SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Suzanne J. Tintle, Alice B. Gottlieb, Psoriatic Arthritis for the Dermatologist, Dermatologic Clinics, 2015, 33, 1, 127

    CrossRef

  2. 2
    Kuldeep Sharma, Kalpeshkumar Giri, Vinay Dhiman, Abhishek Dixit, Mohd Zainuddin, Ramesh Mullangi, A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study, Biomedical Chromatography, 2014, 28, 12
  3. 3
    C. Gaujoux-Viala, J. Nam, S. Ramiro, R. Landewe, M. H. Buch, J. S. Smolen, L. Gossec, Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Annals of the Rheumatic Diseases, 2014, 73, 3, 510

    CrossRef

  4. 4
    J. S. Smolen, R. Landewe, F. C. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, K. Winthrop, M. de Wit, D. Aletaha, N. Betteridge, J. W. J. Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. Cutolo, N. Damjanov, J. M. W. Hazes, M. Kouloumas, T. K. Kvien, X. Mariette, K. Pavelka, P. L. C. M. van Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D. L. Scott, T. Sokka-Isler, J. B. Wong, D. van der Heijde, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases, 2014, 73, 3, 492

    CrossRef

  5. 5
    Kevin L. Winthrop, Hisashi Yamanaka, Hernan Valdez, Eric Mortensen, Robert Chew, Sriram Krishnaswami, Thomas Kawabata, Richard Riese, Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis, Arthritis & Rheumatology, 2014, 66, 10
  6. 6
    Henk M. van Beuningen, Marloes L. de Vries-van Melle, Elly L. Vitters, Wim Schreurs, Wim B. van den Berg, Gerjo J.V.M. van Osch, Peter M. van der Kraan, Inhibition of TAK1 and/or JAK Can Rescue Impaired Chondrogenic Differentiation of Human Mesenchymal Stem Cells in Osteoarthritis-Like Conditions, Tissue Engineering Part A, 2014, 20, 15-16, 2243

    CrossRef

  7. 7
    Satoshi Suzuki, Shinji Morimoto, Maki Fujishiro, Mikiko Kawasaki, Kunihiro Hayakawa, Tomoko Miyashita, Keigo Ikeda, Keiji Miyazawa, Mitsuaki Yanagida, Kenji Takamori, Hideoki Ogawa, Iwao Sekigawa, Yoshinari Takasaki, Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis, Autoimmunity, 2014, 1

    CrossRef

  8. 8
    Leeyen Hsu, April W. Armstrong, JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis, Journal of Immunology Research, 2014, 2014, 1

    CrossRef

  9. 9
    Kamran Ghoreschi, Massimo Gadina, Jakpot! New small molecules in autoimmune and inflammatory diseases, Experimental Dermatology, 2014, 23, 1
  10. You have free access to this content10
    Lindsey A. MacFarlane, Derrick J. Todd, Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis, International Journal of Rheumatic Diseases, 2014, 17, 4
  11. 11
    Mi Kyoung Kim, Heerim Shin, Seo Young Cho, Youhoon Chong, Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group, Bioorganic & Medicinal Chemistry, 2014, 22, 3, 1156

    CrossRef

  12. 12
    Stephan Blüml, Kurt Redlich, Josef S. Smolen, Mechanisms of tissue damage in arthritis, Seminars in Immunopathology, 2014, 36, 5, 531

    CrossRef

  13. 13
    Renata Baronaite Hansen, Arthur Kavanaugh, Novel Treatments with Small Molecules in Psoriatic Arthritis, Current Rheumatology Reports, 2014, 16, 9

    CrossRef

  14. 14
    Eva Salgado, José Ramón Maneiro, Nuevos tratamientos en artritis reumatoide, Medicina Clínica, 2014, 143, 10, 461

    CrossRef

  15. 15
    Sriram Krishnaswami, Vincent Chow, Mary Boy, Cunshan Wang, Gary Chan, Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease, The Journal of Clinical Pharmacology, 2014, 54, 1
  16. 16
    Florian M.P. Meier, Iain B. McInnes, Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety, Best Practice & Research Clinical Rheumatology, 2014,

    CrossRef

  17. 17
    Kirandeep Kaur, Sonesh Kalra, Sandeep Kaushal, Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis, Clinical Therapeutics, 2014, 36, 7, 1074

    CrossRef

  18. 18
    Kunihiro Yamaoka, Yoshiya Tanaka, Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib, Expert Opinion on Pharmacotherapy, 2014, 15, 1, 103

    CrossRef

  19. 19
    Charlotte Rawlings, Ernest Choy, The future of biological agents in the treatment of rheumatoid arthritis, International Journal of Clinical Rheumatology, 2014, 9, 5, 475

    CrossRef

  20. 20
    Kabita Nanda, Carol Ann Wallace, The future of treatment for juvenile idiopathic arthritis, International Journal of Clinical Rheumatology, 2014, 9, 2, 135

    CrossRef

  21. 21
    Xingming Zhang, Fuxiang Liang, Xiaoxue Yin, Xiaojuan Xiao, Peiyu Shi, Dang Wei, Liang Yao, Qi Wang, Yaolong Chen, Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis, Clinical Rheumatology, 2014, 33, 2, 165

    CrossRef

  22. 22
    Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John D. Bradley, David Gruben, Tamas Koncz, Sriram Krishnaswami, Gene V. Wallenstein, Chuanbo Zang, Samuel H. Zwillich, Ronald F. van Vollenhoven, Tofacitinib versus Methotrexate in Rheumatoid Arthritis, New England Journal of Medicine, 2014, 370, 25, 2377

    CrossRef

  23. 23
    Christopher Chang, Unmet needs in the treatment of autoimmunity: From aspirin to stem cells, Autoimmunity Reviews, 2014, 13, 4-5, 331

    CrossRef

  24. 24
    Florian MP Meier, Marc Frerix, Walter Hermann, Ulf Müller-Ladner, Current immunotherapy in rheumatoid arthritis, Immunotherapy, 2013, 5, 9, 955

    CrossRef

  25. 25
    B. Strober, M. Buonanno, J.D. Clark, T. Kawabata, H. Tan, R. Wolk, H. Valdez, R.G. Langley, J. Harness, A. Menter, K. Papp, Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment, British Journal of Dermatology, 2013, 169, 5
  26. 26
    Ying He, Angel YS Wong, Esther W Chan, Wallis CY Lau, Kenneth KC Man, Celine SL Chui, Alan J Worsley, Ian CK Wong, Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis, BMC Musculoskeletal Disorders, 2013, 14, 1, 298

    CrossRef

  27. 27
    Asres Berhan, Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies, BMC Musculoskeletal Disorders, 2013, 14, 1, 332

    CrossRef

  28. 28
    K. Migita, Y. Izumi, T. Torigoshi, K. Satomura, M. Izumi, Y. Nishino, Y. Jiuchi, M. Nakamura, H. Kozuru, F. Nonaka, K. Eguchi, A. Kawakami, S. Motokawa, Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds, Clinical & Experimental Immunology, 2013, 174, 3
  29. 29
    Soumya D. Chakravarty, Poulikos I. Poulikakos, Lionel B. Ivashkiv, Jane E. Salmon, George D. Kalliolias, Kinase inhibitors: A new tool for the treatment of rheumatoid arthritis, Clinical Immunology, 2013, 148, 1, 66

    CrossRef

  30. 30
    Natasha Jordan, Pamela MK Lutalo, David P D’Cruz, Novel therapeutic agents in clinical development for systemic lupus erythematosus, BMC Medicine, 2013, 11, 1, 120

    CrossRef

  31. 31
    Douglas Veale, Psoriatic arthritis: recent progress in pathophysiology and drug development, Arthritis Research & Therapy, 2013, 15, 6, 224

    CrossRef

  32. 32
    Paweł Kawalec, Alicja Mikrut, Natalia Wiśniewska, Andrzej Pilc, The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis, Clinical Rheumatology, 2013, 32, 10, 1415

    CrossRef

  33. 33
    Geom Seog Seo, The Efficacy and Safety of a Tofacitinib in the Treatment of Active Ulcerative Colitis, The Korean Journal of Gastroenterology, 2013, 61, 6, 354

    CrossRef

  34. 34
    Eva Salgado, Juan J Gómez-Reino, The JAK inhibitor tofacitinib for active rheumatoid arthritis: results from Phase III trials, International Journal of Clinical Rheumatology, 2013, 8, 3, 315

    CrossRef

  35. 35
    Chadi Rakieh, Philip G. Conaghan, Tofacitinib for Treatment of Rheumatoid Arthritis, Advances in Therapy, 2013, 30, 8, 713

    CrossRef

  36. 36
    Joon Wan Kim, In Ah Choi, Eun Young Lee, Yeong Wook Song, Eun Bong Lee, Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis, Journal of Korean Medical Science, 2013, 28, 8, 1134

    CrossRef

  37. 37
    Lesley J. Scott, Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis, Drugs, 2013, 73, 8, 857

    CrossRef